Lynne Wagenknecht to F2-Isoprostanes
This is a "connection" page, showing publications Lynne Wagenknecht has written about F2-Isoprostanes.
Connection Strength
2.061
-
Il'yasova D, Wang F, Spasojevic I, Base K, D'Agostino RB, Wagenknecht LE. Racial differences in urinary F2-isoprostane levels and the cross-sectional association with BMI. Obesity (Silver Spring). 2012 Oct; 20(10):2147-50.
Score: 0.432
-
Il'yasova D, Spasojevic I, Base K, Zhang H, Wang F, Young SP, Millington DS, D'Agostino RB, Wagenknecht LE. Urinary F2-isoprostanes as a biomarker of reduced risk of type 2 diabetes. Diabetes Care. 2012 Jan; 35(1):173-4.
Score: 0.414
-
Il'yasova D, Wang F, Spasojevic I, Base K, D'Agostino RB, Wagenknecht LE. Urinary F2-isoprostanes, obesity, and weight gain in the IRAS cohort. Obesity (Silver Spring). 2012 Sep; 20(9):1915-21.
Score: 0.410
-
Il'yasova D, Morrow JD, Wagenknecht LE. Urinary F2-isoprostanes are not associated with increased risk of type 2 diabetes. Obes Res. 2005 Sep; 13(9):1638-44.
Score: 0.269
-
Il'yasova D, Morrow JD, Ivanova A, Wagenknecht LE. Epidemiological marker for oxidant status: comparison of the ELISA and the gas chromatography/mass spectrometry assay for urine 2,3-dinor-5,6-dihydro-15-F2t-isoprostane. Ann Epidemiol. 2004 Nov; 14(10):793-7.
Score: 0.254
-
Melton CD, Luo R, Wong BJ, Spasojevic I, Wagenknecht LE, D'Agostino RB, Il'yasova D. Urinary F2-isoprostanes and the risk of hypertension. Ann Epidemiol. 2017 06; 27(6):391-396.
Score: 0.152
-
Il'yasova D, Wagenknecht LE, Spasojevic I, Watkins S, Bowden D, Wang F, D'Agostino RB. Urinary F2-isoprostanes and metabolic markers of fat oxidation. Oxid Med Cell Longev. 2015; 2015:729191.
Score: 0.130